Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation

Clicks: 478
ID: 112689
1996
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #10 of 105 articles by views in Antimicrobial agents and chemotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Respiratory syncytial virus (RSV) pneumonia in marrow transplant recipients is associated with significant mortality. Ribavirin is a nucleoside analog with activity against RSV and in its aerosolized formulation is the only drug approved for treatment of RSV pneumonia in the United States. The clini …
Reference Key
dm1996antimicrobialphase Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lewinsohn DM;Bowden RA;Mattson D;Crawford SW;;
Journal Antimicrobial agents and chemotherapy
Year 1996
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.